{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T12:59:13Z","timestamp":1784638753482,"version":"3.55.0"},"reference-count":23,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T00:00:00Z","timestamp":1672358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bendamustine and rituximab (BR) is a preferred first\u2010line therapy for indolent non\u2010Hodgkin's lymphoma (iNHL) and mantle cell lymphoma (MCL); however, few reports on BR performance in elderly patients are available to date. We compared safety and efficacy of BR in patients \u226570\u2009years (elderly) vs &lt;70\u2009years (younger) treated at our institution. Among 201 patients, 113 were elderly (median age: 77\u2009years), including 38 patients \u226580\u2009years, and 88 were younger (median age: 62\u2009years). Elderly patients had more bone marrow involvement by lymphoma, anemia, ECOG status 3 and high\u2010risk disease follicular lymphoma (<jats:italic>P<\/jats:italic>\u2009&lt;\u2009.05 for all). Fifty\u2010four percent of elderly received full dose of bendamustine vs 79.5% of younger patients. More elderly patients (54%) vs younger (43.2%) experienced treatment delay. Less elderly proceeded to rituximab maintenance. Overall, the number of adverse events per patient and transformed B\u2010Cell lymphoma\/secondary malignancies were similar between groups. Elderly patients had less febrile neutropenia, rituximab\u2010associated infusion reactions, but more herpes zoster reactivation. There were more deaths in the elderly (37.2%) vs younger (10.2%) groups (<jats:italic>P<\/jats:italic>\u2009&lt;\u2009.001), mainly due to non\u2010lymphoma\u2010related causes. With median follow\u2010up of 42\u2009months [4.0\u201097.0] disease\u2010free survival for the elderly was similar to younger patients. There was no difference between patients &lt;80 and \u226580\u2009years (<jats:italic>P<\/jats:italic>\u00a0=\u00a0.274). In conclusion, the real\u2010world elderly patients have more advanced disease and higher ECOG status. BR is well\u2010tolerated; elderly patients had lower incidence of febrile neutropenia. Dose reduction and treatment delays are common, but BR efficacy was not affected even in very old patients (\u226580\u2009years).<\/jats:p>","DOI":"10.1002\/ijc.34412","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T08:59:44Z","timestamp":1671699584000},"page":"1884-1893","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Bendamustine and rituximab is well\u2010tolerated and efficient in the treatment of indolent non\u2010Hodgkin<scp>'<\/scp>s lymphoma and mantle cell lymphoma in elderly: A single center observational study"],"prefix":"10.1002","volume":"152","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9851-0089","authenticated-orcid":false,"given":"Rouslan","family":"Kotchetkov","sequence":"first","affiliation":[{"name":"Simcoe Muskoka Regional Cancer Program, Royal Victoria Regional Health Center  Barrie Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian R.","family":"Drennan","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, Temerity Faculty of Medicine, Sunnybrook Research Institute, Sunnybrook Health Science Center University of Toronto, Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Susman","sequence":"additional","affiliation":[{"name":"Western University  London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"DiMaria","sequence":"additional","affiliation":[{"name":"Simcoe Muskoka Regional Cancer Program, Royal Victoria Regional Health Center  Barrie Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Gerard","sequence":"additional","affiliation":[{"name":"Simcoe Muskoka Regional Cancer Program, Royal Victoria Regional Health Center  Barrie Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Nay","sequence":"additional","affiliation":[{"name":"Simcoe Muskoka Regional Cancer Program, Royal Victoria Regional Health Center  Barrie Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Prica","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology Princess Margaret Cancer Center  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,12,30]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"Cancer Stat Facts: Non\u2010Hodgkin Lymphoma. National Cancer Institute.https:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2007.1.233"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.01.011"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11040249"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-041863"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2780"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-174961"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2016.09.004"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018\u2010199410020\u201000001"},{"key":"e_1_2_12_14_1","unstructured":"Common terminology criteria for adverse events.https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx097"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-012-1012-2"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32985"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.21018"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006844"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2668-0"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-121909"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2773"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002068"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.34412","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ijc.34412","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.34412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T02:39:03Z","timestamp":1692671943000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.34412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,30]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1002\/ijc.34412"],"URL":"https:\/\/doi.org\/10.1002\/ijc.34412","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,30]]},"assertion":[{"value":"2022-08-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}